Keyphrases
Respiratory Syncytial Virus Infection
100%
Palivizumab
100%
Motavizumab
100%
Respiratory Syncytial Virus
66%
Monoclonal Antibody
50%
High Risk
16%
Hospitalization
16%
Disease Severity
16%
Safety Profile
16%
Therapeutic Potential
16%
Comparative Clinical Study
16%
Fusion Protein
16%
Hospital Admission
16%
Peer Review
16%
Lower Respiratory Infections
16%
Number of Outpatients
16%
Pharmacological Compounds
16%
Respiratory Viral Pathogens
16%
Pharmacology, Toxicology and Pharmaceutical Science
Respiratory Syncytial Virus Infection
100%
Palivizumab
100%
Motavizumab
100%
Human Respiratory Syncytial Virus
66%
Monoclonal Antibody
50%
Disease
16%
Clinical Trial
16%
Infectious Agent
16%
Respiratory Tract Infection
16%
Chimeric Protein
16%